Although systemic routes of administering IGF2 have shown promise in preclinical studies of AD mouse models, administering IGF2 directly into the CNS may be necessary to achieve functional recovery in human AD patients because the mechanisms regulating blood‐to‐brain transport of IGFs may be compromised in AD. Here, IGF2 is linked to Alzheimer disease.